Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines …
Get the latest Viking Therapeutics, Inc. (VKTX) stock news and headlines to help you in your trading and investing decisions.
Viking Therapeutics - Press Releases
Nov 4, 2024 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Viking Therapeutics to Present Data from Phase 2b VOYAGE …
Nov 12, 2024 · Results to be Featured in Oral Late Breaker Presentation. SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver ...
Viking Therapeutics Reports New Data from VK2735 Obesity …
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations ...
Viking Therapeutics to Present Data from Phase 2b VOYAGE …
6 days ago · --Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the ...
Viking Therapeutics Announces Results from Phase 1b Clinical …
Oct 9, 2024 · Highlights from the study results include: Reductions in VLCFAs. In addition to safety and tolerability, the study included an exploratory assessment of changes in plasma levels of VLCFAs after 28...
Viking Therapeutics Reports First Quarter 2024 Financial Results …
SAN DIEGO, April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
Viking Therapeutics Announces Results from Phase 1 Clinical …
Mar 26, 2024 · Safety and Tolerability. Oral VK2735 demonstrated encouraging safety and tolerability following 28 days of once-daily dosing. Among subjects receiving VK2735, all treatment emergent adverse events...
3 Things You Need to Know if You Buy Viking Therapeutics Today
1 day ago · 1. Viking Therapeutics has at least two (maybe four?) major catalysts ahead. Biotech stocks tend to be catalyst-driven. When there's an event that provides new information about the company's ...
Viking Therapeutics Stock Climbs On Positive Data From VK2735 …
Nov 4, 2024 · (RTTNews) - Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company reported positive new clinical data from its VK2735 ...